Fund Details
Overview
Investment portfolio
6rounds
| NAME | DATE | SIZE | |
|---|---|---|---|
Coultreon Biopharma | Apr 2026Participated | $125 MSeries A | |
Aeovian Pharmaceuticals | Dec 2025Led | $55 MSeries B | |
Curve Biosciences | Oct 2025Led | $40 MSeries A | |
Character Biosciences | Mar 2025Led | $93 MSeries B | |
ArsenalBio | Sep 2024Participated | $325 MSeries C | |
ROME Therapeutics | Sep 2023Participated | $72 MSeries B | |
Coultreon Biopharma | Apr 2026Participated | $125 MSeries A | |
Aeovian Pharmaceuticals | Dec 2025Led | $55 MSeries B | |
Curve Biosciences | Oct 2025Led | $40 MSeries A | |
Character Biosciences | Mar 2025Led | $93 MSeries B | |
ArsenalBio | Sep 2024Participated | $325 MSeries C | |
ROME Therapeutics | Sep 2023Participated | $72 MSeries B |
6 Items
6
Items
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Series A | 1 | 1 |
| Series B | 2 | 1 |
| Series C+ | 0 | 1 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Sep '23 | 1 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 0 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 0 |
| Aug '24 | 0 |
| Sep '24 | 1 |
| Oct '24 | 0 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 0 |
| Feb '25 | 0 |
| Mar '25 | 1 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 1 |
| Nov '25 | 0 |
| Dec '25 | 1 |
| Jan '26 | 0 |
| Feb '26 | 0 |
| Mar '26 | 0 |
| Apr '26 | 1 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 6 |
| Enterprise Software | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 0 |
| $5M-$10M | 0 |
| $10M-$25M | 0 |
| $25M-$50M | 1 |
| $50M-$100M | 3 |
| $100M-$250M | 1 |
| $250M-$500M | 1 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 2 of 2 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 5 |
| Europe | 1 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Bristol Myers Squibb | 2 |
| Regeneron Ventures | 2 |
| Section 32 | 2 |
| Sofinnova Ventures | 2 |
| Alexandria Venture Investments | 1 |
| aMoon | 1 |
| Andreessen Horowitz | 1 |
| Apollo Health Ventures | 1 |
| ARCH Venture Partners | 1 |
| Balyasny Asset Management | 1 |
| Bausch & Lomb | 1 |
| Byers Capital | 1 |
| Casdin Capital | 1 |
| Catalio Capital Management | 1 |
| Civilization Ventures | 1 |
| CTI Life Sciences Fund | 1 |
| Eurofarma Ventures | 1 |
| Finchley Healthcare Ventures | 1 |
| First Spark Ventures | 1 |
| Forbion | 1 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 3 | 50% |
| Participating | 3 | 50% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 1 | 33% |
| Co-led | 2 | 67% |
Team
Themasap Khan
Vice President